Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
    • JVI Classic Spotlights
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
    • JVI Classic Spotlights
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Virus-Cell Interactions

RNase L Mediates the Antiviral Effect of Interferon through a Selective Reduction in Viral RNA during Encephalomyocarditis Virus Infection

Xiao-Ling Li, John A. Blackford, Bret A. Hassel
Xiao-Ling Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John A. Blackford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bret A. Hassel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Fig. 1.
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Inducible expression and enzymatic activation of transfected RNase L. (A) RNase L in 100 μg of postmitochondrial supernatant protein from independent transfected cell lines (LS1, LS2, and LS3) was analyzed on Western blots before and 24 h after treatment with 3 mM IPTG. Blots were reacted with a monoclonal antibody specific for transfected human RNase L and with a polyclonal antibody to the constitutively expressed Lac repressor (Stratagene). A film exposed to an ECL (Amersham)-reacted blot is shown. (B) Total RNA from control (C) and RNase L-inducible LS1 cells which had been transfected with 1 μM 2-5A trimer and treated with 1,000 U of murine IFN-α/β (Lee Biomolecular), as indicated, was analyzed on a glyoxal-agarose gel (15 μg of RNA/lane). A Northern blot of this gel was hybridized with an 18S rRNA probe; an autoradiograph of the blot is shown in the lefthand panel. A photograph of the ethidium-stained gel is shown in the righthand panel. Arrows indicate specific rRNA cleavage products.

  • Fig. 2.
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    RNase L enhances the anti-EMCV, but not the anti-VSV, activity of IFN. LS1 cells were treated with the indicated concentrations of murine IFN-α/β for 24 h, in the presence and absence of IPTG (3 mM), to induce RNase L. Cells were then infected with EMCV (A) or VSV (B) at an MOI of 1.0, as described in Materials and Methods. At 18 h PI, viable cells were stained. Data points on the graphs represent means of quadruplicate samples; for each point, the coefficient of variability is ≤3%.

  • Fig. 3.
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    RNase L-dependent reduction in EMCV RNA in IFN-treated cells. (A) Total RNA isolated from LS1 cells following RNase L induction, IFN treatment, and EMCV infection, as indicated, was analyzed on a glyoxal-agarose gel (5 μg of RNA/lane); IFN and IPTG treatments were as described in Materials and Methods, and EMCV infection was for 6 h. The ethidium-stained gel was photographed (lower panel) or transferred to a nylon membrane and hybridized to EMCV and GAPDH cDNA probes; an autoradiograph of these blots is shown in the upper panel. (B) Total RNA isolated from mutant RNase L (SVT2/ZB1) or vector control (SVT2/pSVL) cells following IFN treatment or EMCV infection, as indicated, was analyzed on a glyoxal-agarose gel (7 μg of RNA/lane). A Northern blot of this gel was hybridized to EMCV (upper panel) and GAPDH (lower panel) cDNA probes; an autoradiograph of this blot is shown.

  • Fig. 4.
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    RNase L inhibits EMCV RNA synthesis. (A) LS1 cells were treated with IFN and IPTG, as indicated, and then infected with EMCV in the presence of [3H]uridine, as described in Materials and Methods. Cells were harvested at the indicated times, and [3H]uridine incorporation was determined by TCA precipitation. (B) At 8 h PI, [3H]uridine was removed from the medium and chased with unlabeled UTP and CTP for an additional 2 h; percent RNA remaining was calculated based on TCA-precipitable counts at the beginning of the chase for each treatment. Data points on both graphs are means of six samples at each time point. UNT, untreated (control) cells.

  • Fig. 5.
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    RNase L induction does not alter the cellular RNA profile. (A) The Northern blot shown in Fig. 3A was rehybridized with c-myc (top panel), ISG15 (middle panel), and GAPDH (bottom panel) cDNA hybridization probes; an autoradiograph of the blot is shown. (B) Total RNA from the EMCV-infected cells shown in Fig. 3 (200 ng/reaction) was analyzed by differential display, as described in Materials and Methods; the reverse primer was oligo(dT)11CA, and the forward primers were EMCV specific (5′GAGTCTGTTCTGG3′ [lanes 1 to 5]) or were arbitrary sequence decamers (5′CTGATCCATG3′ [lanes 6 to 9]; 5′CGTAGATCGT3′ [lanes 10 to 13]). An autoradiograph of the gel is shown.

  • Fig. 6.
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    2-5A transfection induces a widespread reduction in cellular RNA. Total RNA from the control and 2-5A-transfected LS1 cells shown in Fig. 1 (200 ng/reaction) was analyzed by differential display, as described in Materials and Methods; the reverse primer was oligo(dT)12A, and the forward primers were 5′TTTTGGCTCC3′ (lanes 1 and 2) or 5′CTTTCTACCC3′ (lanes 3 and 4). An autoradiograph of the gel is shown.

PreviousNext
Back to top
Download PDF
Citation Tools
RNase L Mediates the Antiviral Effect of Interferon through a Selective Reduction in Viral RNA during Encephalomyocarditis Virus Infection
Xiao-Ling Li, John A. Blackford, Bret A. Hassel
Journal of Virology Apr 1998, 72 (4) 2752-2759; DOI:

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
RNase L Mediates the Antiviral Effect of Interferon through a Selective Reduction in Viral RNA during Encephalomyocarditis Virus Infection
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
Share
RNase L Mediates the Antiviral Effect of Interferon through a Selective Reduction in Viral RNA during Encephalomyocarditis Virus Infection
Xiao-Ling Li, John A. Blackford, Bret A. Hassel
Journal of Virology Apr 1998, 72 (4) 2752-2759; DOI:
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

Copyright © 2019 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514